Navigation Links
Drug Treatment Slows Macular Vision Loss in Diabetics

A drug commonly used to slow the loss of central vision has shown promise in stemming a common precursor of blindness in diabetics, which involves the same central// light-sensitive area of retina, Johns Hopkins Wilmer Eye Institute scientists report.

Encouraged by the effect of ranibuzumab in people with macular degeneration, the Hopkins researchers injected the drug into the eyes of 10 people losing their sight from macular edema, one of many complications of diabetes and a first stage of diabetic retinopathy.

Over the course of several months of therapy, every patient in the preliminary Hopkins study could read at least two more lines on the standard eye chart, the researchers said. Moreover, the thickness of the patients’ maculae, the central part of the retina responsible for seeing fine details, decreased an average of 85 percent. The American Journal of Ophthalmology published the team’s findings in their December issue.

“The results are impressive,” says Quan Dong Nguyen, M.D., M.Sc., an assistant professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins, “although we will not know until we begin a larger clinical trial what the long-term benefits of the drug might be.”

The Hopkins group believes that ranibuzumab interferes with a protein that spurs the growth of unwanted blood vessels in the back of the eye. Vascular endothelial growth factor, or VEGF, is released when the oxygen supply in the eye is restricted by blood vessel damage related to diabetes.

In a self-preserving attempt to acquire more oxygen, the VEGF signals for the creation of new blood vessels, which almost always damage, rather than improve, vision by blocking light’s entry onto the retina.

“We’ve suspected for awhile that ranibuzumab’s ability to shut down VEGF’s signaling would do the trick because it’s highly likely that VEGF is the culprit when it comes to diabetic macular edema,” says Nguyen.

More than 4 million diabetics in the United States have diabetic retinopathy and, according to the National Eye Institute, one in 12 of those experience at least some vision loss.

Macular edema, a first stage of retinopathy, occurs when, over time, excess uncontrolled blood sugar damages the tiny blood vessels in the eye, causing fluid and fat to leak onto the retina at the back of the eye. The swelling interferes with focus and blurs vision. Making matters worse, a lack of oxygen often then triggers VEGF’s production cycle.

All 10 subjects in the study had some vision loss at the start of the clinical trial, in which ranibuzumab was administered at the one, two, four and six month marks. The thickness of each patient’s macula was also measured at each point in the study using an advanced digital imaging technique.

“Within a week, several patients experienced dramatic reductions in the thickness of their maculas, and there were further improvements with each injection,” says Peter Campochiaro, M.D., the Dolores and George Eccles Professor of Ophthalmology at The Johns Hopkins University School of Medicine, who is also an investigator in the study.

SourceNewswise
SRM
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... Petersburg, Fla. (PRWEB) , ... February 20, 2017 , ... ... its research and education building. A topping out ceremony on Friday marked the halfway ... The building, set to open in Fall 2018, will serve as a center for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, ... announced during the 2017 Annual HIMSS Conference & Exhibition in Orlando, ... patients and integrating eye care into mainstream healthcare delivery is powered by ...
(Date:2/19/2017)... ... 19, 2017 , ... The Citadel’s new Swain Department of Nursing , ... Amelia Joseph, Ph.D. Joseph was engaged by the college as a consultant to help ... 2016. After a nation-wide search, she was selected to head the department as nurse ...
(Date:2/19/2017)... ... ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... with a glitch reveal in just a few clicks of a mouse. Customizable glitch style ... preset. Use these presets to add a uniquely animated logo to any photos or videos. ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... will join forces with Healthwise ® at HIMSS 2017 to ... leader in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, ... is expected to grow at a CAGR of 9.4% from 2017-2022 ... grow at a CAGR of 9.5% from 2017 to 2027. The ... ... will benefit you Read on to discover how you can ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets has ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
Breaking Medicine Technology: